UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 15, 2020

PIERIS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Nevada (State or other jurisdiction of Incorporation) 001-37471 (Commission File Number) 30-0784346 (IRS Employer Identification No.)

Boston, MA (Address of principal executive offices)

225 State Street, 9th Floor

02109 (Zip Code)

Registrant's telephone number, including area code: 857-246-8998 N/A (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

D Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered		
Common Stock, \$0.001 par value per share	PIRS	The Nasdaq Capital Market		

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure.

Attached hereto as Exhibit 99.1 and incorporated by reference herein is the December 2020 Investor Presentation of Pieris Pharmaceuticals, Inc.

The information set forth under this "Item 7.01. Regulation FD Disclosure," including Exhibit 99.1 attached hereto, shall not be deemed "filed" for any purpose, and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing. except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

99.1 Investor Presentation, Dated December 2020.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PIERIS PHARMACEUTICALS, INC.

Dated: December 15, 2020

/s/ Tom Bures

Tom Bures Vice President, Finance



èris-

INVESTOR PRESENTATION

DECEMBER 2020

Forward Looking Statements

This presentation contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this presentation that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the timing for, and outcome of, the additional in-use and compatibility study for PRS-343 as requested by the FDA; whether data from patients enrolled to date will be sufficient to inform the recommended phase 2 dose for the Company's planned proof of concept study of PRS-343 in gastric cancer; the expected timing and potential outcomes of the reporting by the Company of key clinical data from its programs, references to novel technologies and methods and our business and product development plans, including the advancement of our proprietary and codevelopment programs into and through the clinic and the expected timing for reporting data, making IND filings or achieving other milestones related to our programs, including PRS-060/AZD1402, PRS-343, PRS-344, and PRS-352 and the expected timing of the initiation of the next stage of PRS-343's development in gastric cancer. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates, including our ability to recruit and enroll patients in our studies; our ability to address the requests of the FDA, including with respect to the additional in-use and compatibility study for PRS-343, and the resolution of the partial clinical hold relating to that drug candidate; competition in the industry in which we operate; delays or disruptions due to COVID-19; and market conditions. These forward-looking statements are made as of the date of this presentation, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at www.sec.gov, including without limitation the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and the Company's Quarterly Reports on Form 10-Q.




Improving Lives

2

The Anticalin® Protein Platform

A Novel Therapeutic Class with Favorable Drug-Like Properties

- Human Derived from lipocalins (human extracellular binding proteins)
- Small Monomeric, monovalent, small size (~18 kDa vs 150kDa mAbs)
- Stable Inhalable delivery
- Simple Bi/multispecific constructs
- Proprietary Broad IP position on platform and derived products



Powerful Drug Discovery Platform

- Highly diverse libraries
- Automated screening
- Protein engineering know-how

Translational Science Expertise to Deploy Platform in Meaningful Way

- Immunology expertise underpins IO
 and respiratory focus
- A leader in 4-1BB-related efforts
- Patient phenotyping efforts for improved stratification and novel intervention points in, e.g., asthma



Company Snapshot

Pipeline Highlights Anchor Partnerships PRS-060: Inhaled IL4-Ra antagonist for Validation through three anchor Respiratory: • . • moderate-to-severe asthma (partnered partnerships ✓ PRS-060 phase 2a trial initiation with AstraZeneca) \$120+M in upfront payments and • Data and rationale for advancement into PRS-343: 4-1BB/HER2 bispecific for solid . IND-enabling studies for wholly-owned milestones since January 2017 tumors inhaled program Each partnership includes options for . • Next-generation respiratory: Includes 4 . 10: co-development & US-focused discovery-stage inhaled therapeutics PRS-343 complete monotherapy and 1 commercialization rights programs (2 proprietary, 2 partnered with combination with atezolizumab phase 1 . Value-driving opt-in for PRS-060 after AstraZeneca) escalation data at ESMO phase 2a completion · 4-1BB-based bispecifics: Multiple PRS-343 initiation of 2nd line HER2+ proprietary and partnered 4-1BB-based gastric cancer PoC study, additive to SoC programs for IO PRS-344 IND 4 Improving Lives pieris

Partnerships



Strong Partners • Significant Cash Flow • Retained Commercial Rights




Pipeline

CANDIDATE	TARGETS	PARTNER	COMMERCIAL RIGHTS	DISCOVERY	PRECLINICAL	PHASE I	PHASE II
PRS-060/AZD1402	IL4-Ra	AstraZeneca	Pieris Worldwide Profit-Share Option		in in		
AstraZeneca Programs*	n.d.	AstraZeneca	Pieris Worldwide Profit-Share Option*				
Proprietary Programs	n.d.	n/a	Pieris Worldwide				

CANDIDATE	TARGETS	PARTNER	COMMERCIAL RIGHTS	DISCOVERY	PRECLINICAL	PHASE I	PHASE II
PRS-343	HER2/4-1BB	n/a	Dia da Mandal da		ko da		
	+ Anti-PD-L1	n/a	Pieris Worldwide	T			
PRS-344	PD-L1/4-1BB	* SERVIER	Pieris U.S. Rights				
PRS-352	n.d.	* A	* Servier				
Proprietary IO Programs	n.d.	n/a	Pieris Worldwide				
Seattle Genetics Program [‡]	co-stim agonist	OSeattleGenetics	Pieris U.S. Option [‡]				



Anticalin Technology Advantages: Differentiated Respiratory Platform



Candidate	PRS-060	
Function/MoA	Inhibiting IL4-R α (disrupts IL-4 & IL-13 signaling)	
Indications	Moderate-to-severe asthma	
Development	Phase 2a in moderate asthmatics	X
Commercial Rights	Co-development and U.S. co-commercialization rights, including gross margin share	PRS-060



PRS-060 Phase I Multiple Ascending Dose Trial

Strategic Objectives	Ascertain PK/PD with a reliable biomarker to confirm local target engagement and inform Phase II dosage regimen					
Trial Design Highlights	osing patients with mild asthma with elevated FeNO levels (≥35 ppb), to receive haled PRS-060 or pbo b.i.d.* over a 10-day period					
Initiated in July 2018	*q.d. on Day 10					
Evaluating safety, toler PD and will also evaluation vs. placebo						

Measuring safety, tolerability and FeNO changes days 1-10,17, and 40

Pieris is sponsoring the trial, AstraZeneca is reimbursing Pieris for all associated costs



Phase 1b Interim Results: Favorable Safety Profile

- All doses of AZD1402/PRS-060 tested in the study were well tolerated
- No treatment-related serious AEs were observed


System organ class AE Preferred Terms ^b	Placebo (N = 12) n (%) m	AZD1402/PRS-060 [∞] (N = 30) n (%) m	Overall (N = 42) n (%) m
Gastrointestinal disorders	4 (33.3) 4	13 (43.4) 14	17 (40.5) 18
Dry mouth	1 (8.3) 1	2 (6.7) 2	3 (7.1) 3
Nausea	1 (8.3) 1	3 (10.0) 3	4 (9.5) 4
Infections and infestations	1 (8.3) 1	7 (23.3) 8	8 (19.0) 9
Upper respiratory tract infection	1 (8.3) 1	3 (10.0) 4	4 (9.5) 5
Nervous system disorders	5 (41.7) 9	13 (43.4) 18	18 (42.9) 27
Headache	3 (25.0) 6	5 (16.7) 7	8 (19.0) 13
Presyncope	0	4 (13.3) 6	4 (9.5) 6
Respiratory, thoracic and mediastinal disorders	6 (50.0) 6	14 (46.7) 15	20 (47.6) 21
Cough	1 (8.3) 1	4 (13.3) 4	5 (11.9) 5
Rhinorrhoea	2 (16.7) 2	1 (3.3) 1	3 (7.1) 3
Wheezing	2 (16.7) 2	4 (13.3) 5	6 (14.3) 7



Improving Lives

10

Phase 1b Interim Results: Robust FeNO Reduction




PRS-060, mg (delivered)	n	Reduction vs. placebo, % (95% Cl)	p-value
2	6	24.0 (1.8-41)	0.04
6	6	24.3 (2.7-41)	0.03
20	12	36.4 (22-48)	< 0.0001
60	6	30.5 (10-46)	0.005
Placebo	12		

PRS-060 Relative FeNO Reduction (Emax Analysis)

PRS-060 Relative FeNO Reduction (ANCOVA Analysis)

Mean change from baseline in FeNO levels at 0.5h (A) and 2h (B) post-dose on Day 10 in participants with mild asthma




-pieris-

Improving Lives

11

Phase 1b Interim Results: Pharmacological Versatility



pSTAT6 levels over time following inhalation of PRS-060

No systemic target engagement and systemic minimal exposure was observed at the 2mg dose, suggesting that local target engagement by the drug is sufficient to reduce airway inflammation

Pharmacological versatility, given lowdose FeNO reduction with no observed systemic activity (pSTAT6) versus high-dose FeNO reduction systemic activity

PRS-060 Phase 2a Trial

Part 1	Patient Population: Moderate controlled asthmatics Primary Endpoint: Safety and tolerability Number of Patients: ~45
Part 2	Patient Population: Moderate uncontrolled asthmatics with blood eosinophil count of $\ge 150 \text{ cells}/\mu\text{L}$ and FeNO $\ge 25 \text{ ppb}$ at screening Primary Endpoint: Improvement of FEV1 over four weeks relative to placebo Number of Patients: ~360
First patient dosed expect	ed 1Q2021
Dry powder formulation, a four weeks	dministered b.i.d. over

Up to three dose levels plus placebo

Study is sponsored and funded by AstraZeneca



-pieris-

4-1BB Agonism Offers Promise of Material Clinical Benefit

Unique Attributes of 4-1BB Agonism on Tumor-specific T Cells

- ✓ Increases T-cell proliferation to bolster immune repertoire
- ✓ Enhances cytotoxicity for tumor killing
- ✓ Improves metabolic fitness for increased survival of T cells
- ✓ Drives T-cell memory phenotype for increased durability

Pieris' 4-1BB bispecifics recognize that 4-1BB agonists have proven clinical potency, yet must be kept out of the liver to ensure suitable therapeutic index



Improving Lives


14

PRS-343: Proprietary Lead IO Asset

Candidate	PRS-343	HER2-Targetin Antibody
Function/MoA	Tumor-targeted 4-1BB agonism and HER2 antagonism	
Indications	HER2+ solid tumors	
Development	Initiating phase 2 in combination with ramucirumab and paclitaxel in second line gastric	
Commercial Rights	Fully proprietary	4-1BB-Targetin Anticalin Protein



PRS-343 Localizes 4-1BB Agonism Within HER2+ Tumors



Monotherapy and Combination Studies: Enabled Meaningful Clinical Characterization of PRS-343

Snapshot

- · Patients with HER2+ solid tumors
- · Monotherapy and combination with atezolizumab
- Data updates presented at ESMO 2020

Primary Objectives

Secondary Objectives

- Characterize safety profile
- Identify MTD or RP2D
- Characterize PK profile
- Investigate dosing schedule
- Assess potential immunogenicity and PD effects
- Investigate efficacy

Schedule 1: Q3W dosing on day 1; 21-day cycle

Schedule 2 (b): Q2W dosing on days 1, 15; 28-day cycle

Schedule 3 (c): Q1W dosing on days 1, 8, 15; 21-day cycle

In combination with atezolizumab: Q3W dosing on day 1; 21-day cycle

Mono Dose Cohort*	Combo Dose Cohort**	Dose (mg/kg)
1		0.0005
2		0.0015
3		0.005
4		0.015
5	1	0.05
6	2	0.15
7	3	0.5
8	4	1
9	5	2.5
10	6	5
11	7	8
11 (b)		8
11 (c)		8
12 (b)		12
13 (b)		18
Obinutuzumab + 11(b)		8

9-13b: active dose cohorts in mono study

*Additional dose cohorts enrolling in monotherapy study **1200mg flat dose of atezolizumab



ACTIVE

SCHEDULES


Based on clinical data, serum concentration of > 20 µg/ml defines active dose range (beginning at Cohort 9)

Cohort	13b	12b	11c	Obi	11b	11	10	9	
Best Response	18 mg/kg, Q2W	12 mg/kg, Q2W	8 mg/kg, QW	8 mg/Kg, Q2W	8 mg/kg, Q2W	8 mg/kg, Q3W	5 mg/kg, Q3W	2.5 mg/kg, Q3W	Total
Evaluable Patients	3	2	4	2	7	4	6	5	33
CR	1		÷			÷			1
PR					3	7)	-	.73	3
SD	÷	a.	1	1	3	3	3	2	13
ORR	33%	0%	0%	0%	43%	0%	0%	0%	12%
DCR	33%	0%	25%	50%	86%	75%	50%	40%	52%

Data cut-off: 27-Jul-20



Increase in CD8+ T Cells and Circulating Soluble 4-1BB Support 4-1BB Engagement by PRS-343



Phase 2 PoC Study in 2nd Line Gastric Cancer

Phase 2 Initiation

PRS-343 in combination with ramucirumab and paclitaxel for 2nd-line HER2+ gastric cancer

Clinical trial collaboration with Eli Lilly; Lilly to supply ramucirumab

Single-arm, up to 60 patients

Primary endpoints: ORR and DCR

HER2+ subgroup from RAINBOW trial as comparator enriched w/ RWD

-pieris-

Improving Lives

GC 2L PIVOTAL TRIAL

20

PRS-343 PoC Trial Considers Several Value-driving Elements


Factor	Impact	
Biology: Synergistic MoA in IO-amenable Patients	 Vasculature normalization from ramucirumab for improved environment for T-cell infiltration Tumor debulking and antigen release from paclitaxel for improved disease control and enhanced immune priming 	
Regulatory: Additive to Standard of Care	 Straightforward path from PoC to pivotal Reduced patient enrollment hurdles compared to monotherapy study 	
Commercial: Meaningful Beachhead Indication	 Second line gastric cancer market size in US, EU5, and JP is up to \$1.7B Upside in several other tumors 	
-pieris-	Improving Lives	21

PRS-344: Meaningfully Building on Localized MoA of PRS-343

Candidate	PRS-344	PD-L1-Targeting Antibody
Function/MoA	Localized 4-1BB agonism with PD-L1 antagonism	
Indications	N.D.	
Development	2021 IND expected (in co-dev with Servier)	
Commercial Rights	Opt-in for co-development with full U.S. commercial rights; royalty on ex-U.S. sales	4-1BB-Targeting Anticalin Proteins



Financial Overview (As of 9/30/20)





Baseline Characteristics : Monotherapy and Combination with Atezolizumab

All Subjects (n = 74, 41)

Characteristic	Monotherapy; n (%)	In Combination with Atezolizumab; n (%)	Primary Cancer Type	Monotherapy; n (%)	In Combinati Atezolizumat
Age, Median (range)	63 (24–92)	59 (26-87)	Gastroesophageal	27 (36%)	7 (17%)
Gender				()	. (
F	44 (59%)	23 (56%)	Breast	16 (22%)	12 (29%
М	30 (41%)	18 (44%)	Coloraatal	10 (1404)	5 (100/)
ECOG PS*			Colorectal	10 (14%)	5 (12%)
0	19 (26%)	12 (29%)	Gynecological	9 (12%)	4 (10%)
1	55 (74%)	18 (44%)			61 - 61
Prior Therapy Lines			Biliary Tract	7 (9%)	6 (15%)
1	9 (12%)	5 (12%)	N- 0- 10-11	ō	4 (10%)
2	10 (14%)	7 (17%)	Non-Small Cell Lung		
3	15 (21%)	6 (15%)	Bladder	2 (3%)	1 (2%)
4	11 (15%)	6 (15%)	Didddei	2 (070)	1 (2 70)
5+	28 (38%)	17 (41%)	Pancreatic	1 (1%)	1 (2%)
Median no. of anti-HER2 Treatments			Other – Cancer of Unknown Origin	1 (1%)	1 (2%)
Breast	7	3-4			
Gastric	3	1	Other - Salivary Duct	1 (1%)	-

*Combination trial enrolled ECOG 2 patients as well (not shown on this chart)



Improving Lives

25

Data cut-off: 27-Jul-20



Treatment-Related Adverse Events (Monotherapy Trial) All Subjects

	Monot	herapy
Occurred in > 1 Patient	n = 145 (%)	% Grade 3
Infusion Related Reaction	27 (19%)	3 (2%)
Fatigue	11 (8%)	1 (1%)
Nausea	11 (8%)	
Vomiting	8 (6%)	
Chills	8 (6%)	
Anemia	2 (1%)	1 (1%)
Arthalgia	2 (1%)	
Asthenia	2 (1%)	
Cough	2 (1%)	
Decreased appetite	2 (1%)	
Diarrhea	6 (4%)	
Dizziness	2 (1%)	
Dyspnoea	3 (2%)	
Flushing	5 (3%)	2 (1%)
Non-cardiac chest pain	4 (3%)	
Paraesthesia	3 (2%)	1 (1%)
Pruritis	3 (3%)	
Rash	2 (1%)	

One TRAE above Grade 3: Grade 4 Infusion Related Reaction in cohort 10 (5mg/kg PRS-343, Q3W).


Data cut-off: 27-Jul-20




Improving Lives

27


Average Time on Treatment with PRS-343 Cohorts 9-11a



Average Time on Treatment with PRS-343 Cohorts 11b-13b



Best Response in Target Lesions (Monotherapy Trial) Cohorts 9-13b



Case Study: Gastric Cancer Patient with Confirmed Partial Response Patient Profile, Treatment History and Treatment Outcome

 Patient Profile Cohort 11b 8 mg/kg every two weeks 80-year old woman; initial diagnosis in June 2017 Stage IV gastric adenocarcinoma Metastases to liver, lymph node and adrenal glands HER2 IHC 3+; PD-L1 positive (CPS=3) NGS: ERBB2 amplification, TP53 mutation, alteration of CDK12 and SF3B1 		Trastuzu Cape Nivolum	gy Treatment History mab, Pembrolizumab + citabine/oxaliplatin ab with IDO1 inhibitor estigational drug)	Duration July 2017 – June 2018 Aug 2018 – Jan 2019	 CC - 2mg HE Good Appel Density - 	
Lesions	Lesion Site			Lesion Size (mm)		
	Lesion Site	Baseline	C2 Post-treatment	C3 Post-treatment	C4 Post-treatment	C6 Post-treatment
Target 1	Liver	14	12	10	9	8
Target 2	Liver	20	16	10	8	9
Target 3	Pancreas	19	16	14	14	14
% Change from Baseline			-17%	-36%	-42%	-42%
Non-target 1	Lung	Present	Present	Present	Present	Present

Non-target 1 Lung Present Present Present Non-target 2 Stomach Present Present Present Non-target 3 Stomach Present Present Present



Improving Lives

Absent


Absent

Data cut-off: 24-Jan-20

Present

Present

CD8+ T Cell Numbers in the Tumor and Circulating s4-1BB Increase Post-Treatment in Responding Gastric Cancer Patient



Case Study #2: Rectal Cancer Patient with Confirmed Complete Response Patient Profile, Treatment History and RECIST

Datiant Drafila	Oncology Treatment History	Duration
Patient Profile Cohort 13b 18 mg/kg Q2W	Capecitabine + XRT	Apr-May 2017
 59-year-old male; initial diagnosis March 2017 	Neoadjuvant Folfox	May-Sep 2017
Stage 4 rectal adenocarcinoma cancer; metastasized to	Resection	Dec 2017
heart and lung	Folfiri/Avastin	Mar-Jul 2018
 FoundationOne Her2 amplification; in-house testing IHC 3+ 	5FU/Avastin maintenance	Aug 2018-May 2019
 MSS, TMB low (2 mt/Mb) 	Irinotecan/Avastin	May-Nov 2019
	SBRT	Nov 2019


		Lesion Size (mm)					
Lesions	Lesion Site	Baseline	C2 Post-treatment	C4 Post-treatment	C6 Post-treatment		
Target 1	Lung	22	13	0	0		
% Change from Baseline			-41%	-100%	-100%		
Non-target 1		Present	Present Absent		Absent		

Data cut-off: 27-Jul-20



Improving Lives

CD8+ T Cell Numbers in the Tumor and Circulating s4-1BB Increase Post-Treatment in CR Rectal Cancer Patient





Combination Therapy with Atezolizumab

Treatment-Related Adverse Events (Combination Trial) All Subjects

Occurred in a Dation	Combination wi	th Atezolizumab	
Occurred in > 1 Patient	n = 148 (%)	% Grade 3	
Infusion Related Reaction	38 (26%)	3 (2%)	
Fatigue	12 (8%)		
Nausea	8 (5%)		
Vomiting	38 (26%)		
Abdominal pain	2 (1%)		
Anemia	4 (3%)	2 (1%)	
Anorexia	2 (1%)		
Arthalgia	2 (1%)		
Diarrhea	5 (3%)	1 (1%)	
Dry mouth	3 (2%)		
Fever	3 (2%)		
Lightheadness	2 (1%)		
Lymphocyte count decreased	3 (2%)	1 (1%)	
Neutrophil count decreased	3 (2%)	1 (1%)	
Peripheral sensory neuropathy	2 (1%)		
Pruritis	4 (3%)		

Two TRAEs above Grade 3: Grade 4 AST increase, Grade 3 transaminitis, and eventually Grade 5 hepatic failure in cohort 7 (8mg/kg + 1200mg atezolizumab); Grade 4 hemolytic anemia (unrelated to PRS-343, related to atezolizumab) in cohort 7.

Data cut-off: 27-Jul-20



Improving Lives

Summary of Responses of PRS-343 in Combination with Atezolizumab


Cohort	7	6	5	4		
Best Response	8mg/kg, Q3W	mg/kg, Q3W 5mg/kg, Q3W		1mg/kg, Q3W	Total	
Evaluable Patients	8	8	8	3	27	
PR	1	2	-	1	4	
SD	4	1	1	0	6	
ORR	13%	25%	0%	33%	15%	
DCR	63%	38%	13%	33%	37%	

Data cut-off: 27-Jul-20




Improving Lives


Soluble 4-1BB Increases in Active Dose Cohorts & Clinical Benefit is Associated with Tumoral Immune Cell Activation



PRS-343 + Atezolizumab Duration of Exposure



Best Response in Target Lesions (Combination Study) Cohorts 4-7





Improving Lives

Case Study: Breast Cancer Patient with Stable Disease (Update) Patient Profile, Treatment History and RECIST

Datiant Drafiles	Oncology Treatment History	Duration	
Patient Profile: Cohort 6 5 mg/kg Q3W + 1200mg atezolizumab	Trastuzumab/Docetaxel/ Tamoxifen/Carboplatin	Sep 2011-Jul 2013	
 52-year-old male; Initial diagnosis July 2011 Stage 2 Invasive Ductal Breast Cancer 	Trastuzumab/Pertuzumab/Vinorelbine	Aug 2013-Jan 2016	
FISH HER2/CEP17 ratio 2.4, HER2 copy number 4.8	T-DM1/Fulvestrant	Nov 2017-Mar 2018	
In-house testing IHC2+, FISH+ PD-L1 low in pre-treatment and high in post treatment biopsy 	Capecitabine/Lapatinib	Mar 2018	
	Palbociclib/Arimidex	Apr-May 2019	


Lesions Lesion Site		Lesion Size (mm)						
	Baseline	C2 Post- treatment	C4 Post- treatment	C6 Post- treatment	C8 Post- treatment	C12 Post- treatment	C16 Post- treatment	
Target 1	right pulmonary ligament lymph node	16	18	15	13	13	6	5
% Change from Baseline			+12.5%	-6%	-19%	-19%	-63%	-69%
Non-target 1-4		Present	Present	Present	Present	Present	Present	Present

Data cut-off: 27-Jul-20



Improving Lives

Tumoral and Circulating s4-1BB Increase Post-Treatment in PR Breast Cancer Patient



CD8⁺ T cell numbers, proliferation, cytolytic molecules and s4-1BB increase post-treatment, demonstrating 4-1BB arm activity of PRS-343



Improving Lives

Pieris Pharmaceuticals

255 State Street Boston, MA 02109 USA Zeppelinstraße 3 85399 Hallbergmoos Germany

> IR: kelman@pieris.com BD: niemeier@pieris.com www.pieris.com

S

NASDAQ: PIRS